Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Illumina

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

Upgrades

Benzinga

Illumina Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 11 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Illumina Stock In The Last 15 Years

Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 9.39% on an annualized basis producing an average annual return of 15.68%. Currently, Illumina has a market capitalization of $29.25 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 10 years by 6.06% on an annualized basis producing an average annual return of 16.76%. Currently, Illumina has a market capitalization of $30.53 billion.

Benzinga

A Beaten-Down Biotech Stock That's Finally Attractive

This lab-hardware business is growing, cashed up, and close to profitability.

The Street

If You Invested $100 In Illumina 15 Years Ago, Here's How Much You Would Have Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 11.83% on an annualized basis producing an average annual return of 18.76%. Currently, Illumina has a market capitalization of $36.40 billion.

Benzinga

Why Illumina Shares Are Plunging Today?

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ:ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by Illumina, namely, U.S.…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Where Illumina Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Illumina (NASDAQ:ILMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Stock Market Pares Losses As Nasdaq Falls 1.4%; Jobs Report Offers Mixed Signals

The Russell 2000 dropped to the lowest level since December 2020.

Investors Business Daily

If You Invested $1000 In Ilumina 10 Years Ago, Here's How Much You Would Have Today

Illumina (NASDAQ:ILMN) has outperformed the market over the past 10 years by 7.06% on an annualized basis producing an average annual return of 18.79%. Currently, Illumina has a market capitalization of $39.64 billion.

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Benzinga

DNA Giant Illumina Smashes Profit Views, Though Sales Just Meet

Illumina crushed earnings forecasts on Thursday, though the next-generation DNA sequencer just met sales views. Illumina stock was unchanged.

Investors Business Daily

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Benzinga

Here's How Much You Would Have Made Owning Illumina Stock In The Last 5 Years

Illumina (NASDAQ:ILMN) has outperformed the market over the past 5 years by 1.75% on an annualized basis producing an average annual return of 15.45%. Currently, Illumina has a market capitalization of $56.36 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyst Ratings For Illumina

Illumina (NASDAQ:ILMN) has observed the following analyst ratings within the last quarter:

Benzinga

Illumina Launches Multiple-Gene Diagnostic Test For Cancer Patients

Illumina Inc (NASDAQ: ILMN) has launched TruSight Oncology (TSO) Comprehensive (EU), a

StockNews.com

Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?

The diagnostics and research industry has grown substantially over the past few years with the integration of advanced technologies and impressive breakthroughs in the early diagnosis of chronic diseases. Given the growing investments in this industry, prominent companies Illumina (ILMN) and Qiagen (QGEN) are well-positioned to benefit. Let’s find out…

Benzinga

What 5 Analyst Ratings Have To Say About Illumina

Analysts have provided the following ratings for Illumina (NASDAQ:ILMN) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings For Illumina

Over the past 3 months, 5 analysts have published their opinion on Illumina (NASDAQ:ILMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

10 Biggest Price Target Changes For Friday

SVB Leerink cut Illumina, Inc. (NASDAQ: ILMN) price target from $430 to $400. Illumina shares fell 0.7% to $355.70 in pre-market trading.

Benzinga

Illumina's Q4 Profit Falls Despite Topline Growth Of 26%

Illumina Inc (NASDAQ: ILMN) reported

Benzinga

Illumina: Q4 Earnings Insights

Illumina (NASDAQ:ILMN) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Illumina beat estimated earnings by 53.06%, reporting an EPS of $0.75 versus an estimate of $0.49.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.